EISAI CO

🇯🇵Japan

Country: 🇯🇵Japan

Ownership: Public

Established: 1941-12-06

Employees: 11K

Market Cap: $12B

Website: http://www.eisai.co.jp

Clinical Trials

Study to Assess the Safety, Tolerability, and Pharmacokinetics of E2082 in Healthy Male Subjects

Phase 1

Terminated

Conditions: Healthy Participants

Interventions: Drug: Placebo
Drug: E2082

First Posted Date: 2018-01-18

Last Posted Date: 2021-06-30

Lead Sponsor: Eisai Co., Ltd.

Target Recruit Count: 118

Registration Number: NCT03402178

Locations: 🇯🇵
Eisai Trial Site, Sumida-ku, Tokyo, Japan

Bioequivalence Study Between a 4-mg Dose of Fine Granules of Perampanel and a 4-mg Tablet of Perampanel in Healthy Japanese Subjects

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: Perampanel

First Posted Date: 2018-01-16

Last Posted Date: 2018-10-29

Lead Sponsor: Eisai Co., Ltd.

Target Recruit Count: 24

Registration Number: NCT03399734

Locations: 🇯🇵
Eisai Trial Site, Toshima-ku, Tokyo, Japan

Study of E7389 Liposomal Formulation in Participants With Solid Tumor

Phase 1

Active, not recruiting

Conditions: Solid Tumor

Interventions: Drug: E7389-LF

First Posted Date: 2017-07-05

Last Posted Date: 2024-11-05

Lead Sponsor: Eisai Co., Ltd.

Target Recruit Count: 140

Registration Number: NCT03207672

Locations: 🇯🇵
Eisai Trial Site 5, Sapporo, Hokkaido, Japan
🇯🇵
Eisai Trial Site 1, Chuo-ku, Tokyo, Japan
🇯🇵
Eisai Trial Site 10, Hidaka, Saitama, Japan

and more 9 locations

Study for Verification of Efficacy and Safety for Perampanel Monotherapy in Untreated Participants With Partial Onset Seizures (Including Secondarily Generalized Seizures (FREEDOM Study)

Phase 3

Completed

Conditions: Partial Onset Seizures

Interventions: Drug: E2007

First Posted Date: 2017-06-28

Last Posted Date: 2021-08-05

Lead Sponsor: Eisai Co., Ltd.

Target Recruit Count: 91

Registration Number: NCT03201900

Locations: 🇯🇵
Eisai Trial Site #29, Fukuoka, Japan
🇯🇵
Eisai Trial Site #30, Miyagi, Japan
🇯🇵
Eisai Trial Site #10, Kyoto, Japan

and more 35 locations

Investigation of the Clinical Safety and Efficacy of Long-term Treatment With Fycompa Tablets in Adolescence Epilepsy Patients With Partial-onset Seizures (With or Without Secondary Generalized Seizures) or Primary Generalized Tonic-clonic Seizures

Completed

Conditions: Partial Seizures (With or Without Secondary Generalized Seizures)
Primary Generalized Tonic-clonic Seizures

Interventions: Drug: Fycompa

First Posted Date: 2017-02-23

Last Posted Date: 2022-08-05

Lead Sponsor: Eisai Co., Ltd.

Target Recruit Count: 519

Registration Number: NCT03059381

Investigation of the Clinical Safety and Efficacy of Long-term Treatment With Fycompa Tablets in Adult Epilepsy Patients With Partial-onset Seizures (With or Without Secondary Generalized Seizures) or Primary Generalized Tonic-clonic Seizures

Completed

Conditions: Partial Seizures (With or Without Secondary Generalized Seizures)
Primary Generalized Tonic-clonic Seizures

Interventions: Drug: Fycompa

First Posted Date: 2017-02-23

Last Posted Date: 2022-03-02

Lead Sponsor: Eisai Co., Ltd.

Target Recruit Count: 3809

Registration Number: NCT03059329

A Study on Safety and Efficacy in Patients With Soft Tissue Sarcomas

Completed

Conditions: Sarcoma, Soft Tissue

Interventions: Drug: Eribulin mesylate

First Posted Date: 2017-02-20

Last Posted Date: 2020-04-06

Lead Sponsor: Eisai Co., Ltd.

Target Recruit Count: 256

Registration Number: NCT03058406

Study to Evaluate the Safety and Tolerability of a Once Daily Dose of 50 mg E2609 in Healthy Japanese Subjects

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: E2609
Drug: Placebo

First Posted Date: 2017-02-16

Last Posted Date: 2017-04-18

Lead Sponsor: Eisai Co., Ltd.

Target Recruit Count: 16

Registration Number: NCT03055962

Locations: 🇯🇵
Eisai Trial Site, Fukuoka, Japan

Pharmacokinetic Study of E7080/Lenvatinib in Chinese Subjects With Solid Tumor

Phase 1

Completed

Conditions: Solid Tumor

Interventions: Drug: lenvatinib

First Posted Date: 2017-01-04

Last Posted Date: 2021-09-28

Lead Sponsor: Eisai Co., Ltd.

Target Recruit Count: 12

Registration Number: NCT03009292

Locations: 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
🇨🇳
Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China

A Study of Tazemetostat in Participants With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma

Phase 1

Completed

Conditions: Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma

Interventions: Drug: Tazemetostat

First Posted Date: 2017-01-04

Last Posted Date: 2022-11-10

Lead Sponsor: Eisai Co., Ltd.

Target Recruit Count: 7

Registration Number: NCT03009344

Locations: 🇯🇵
Eisai Trial Site, Chuo-ku, Tokyo, Japan

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy